GlobeNewswire: Dignity Sciences Limited Contains the last 10 of 3 releaseshttp://www.globenewswire.com/External?Length=42024-03-19T02:58:35ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2015/01/05/694780/10113956/en/Positive-Pre-Clinical-Results-for-Non-Alcoholic-Steatohepatitis-NASH-with-Anti-fibrotic-DS102-Bioactive-Lipid.html?f=22&fvtc=4&fvtv=22487Positive Pre-Clinical Results for Non-Alcoholic Steatohepatitis (NASH) with Anti-fibrotic DS102 Bioactive Lipid2015-01-05T06:33:33Z<![CDATA[Dignity Sciences today announced positive results with its anti-fibrotic compound DS102 in preclinical studies which assessed its potential effectiveness for the treatment of non-alcoholic steatohepatitis (NASH). DUBLIN, Ireland, Jan. 5, 2015 (GLOBE NEWSWIRE) -- via PRWEB - DS102 was tested in an In Vivo Efficacy STAM™ model, an indication specific standard for NASH, over two different time periods, all of which demonstrated a clear potential for the treatment of NASH with DS102. The STAM™ model is created by a combination of chemical and dietary interventions in C57BL/6 mice. ]]>https://www.globenewswire.com/news-release/2014/07/30/654349/10091875/en/DS107G-01-Successful-Completion-of-Phase-I-Oral-DGLA-Clinical-Trial.html?f=22&fvtc=4&fvtv=22487DS107G-01 - Successful Completion of Phase I Oral DGLA Clinical Trial2014-07-30T05:03:39Z<![CDATA[Dignity Sciences Limited finds that orally administered DGLA distributes well to the skin resulting in high dermal bioavailability DUBLIN, Ireland, July 30, 2014 (GLOBE NEWSWIRE) -- via PRWEB - Dignity Sciences Limited, a privately held biopharmaceutical company, today announced the successful completion of a Phase I trial with DS107G, an oral formulation of Dihomo Gamma Linolenic Acid (DGLA).]]>https://www.globenewswire.com/news-release/2014/07/08/649174/10088437/en/DS107E-02-Positive-Phase-II-Results-in-Atopic-Dermatitis.html?f=22&fvtc=4&fvtv=22487DS107E-02 - Positive Phase II Results in Atopic Dermatitis2014-07-08T06:03:30Z<![CDATA[Dignity Sciences Limited finds that a DGLA topical cream (DS107E) has an overall dose response improvement for Atopic Dermatitis in a Phase II clinical trial. DUBLIN, Ireland, July 8, 2014 (GLOBE NEWSWIRE) -- via PRWEB - Dignity Sciences Limited, a privately held biopharmaceutical company, today announced positive Phase II results for DS107E (DGLA cream), as a topical treatment for atopic dermatitis.]]>